CDK7 Inhibitor Combination Therapy for Resistant Cancer Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for new and improved treatment modalities for proliferative diseases, particularly cancer, as existing CDK7-inhibitors have shown limited clinical activity and there is a requirement to enhance the efficacy of existing therapies.

Innovation Solution

A combination therapy involving a cyclin-dependent kinase 7 (CDK7) inhibitor and a distinct anti-cancer agent, such as immune checkpoint inhibitors, PARP inhibitors, or cytotoxic compounds, which can be administered together or separately, to enhance treatment efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CDK7 inhibitors are used as monotherapy, then the treatment targets proliferation pathways, but the clinical activity is limited

Engineering Contradiction:

Improveclinical activityVSAvoidtreatment efficacy

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent combines CDK7 inhibitors with other anti-cancer agents (immune checkpoint inhibitors, PARP inhibitors, cytotoxic compounds) to create a combination therapy that achieves synergistic anti-tumor effects, overcoming the limited clinical activity of monotherapy

Inventive Principle:

Principle #5Merging (Combining)

2Productivity

If existing anti-cancer therapies are used, then treatment is provided, but the efficacy needs to be enhanced

Engineering Contradiction:

Improvetreatment efficacyVSAvoidanti-tumor efficacy

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent changes the therapeutic parameter by introducing combination therapy with specific dosing regimens and administration schedules, thereby enhancing the anti-tumor efficacy beyond what single agents can achieve

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If monotherapy is used, then treatment is simple, but cancer cells may be resistant

Engineering Contradiction:

Improvetreatment simplicityVSAvoidsensitivity restoration

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent converts the resistance mechanism into a vulnerability by combining CDK7 inhibitors with other agents that target complementary pathways, thereby restoring sensitivity in resistant cancer cells while maintaining treatment feasibility

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20260041693A1Combination therapy of CDK7 inhibitors with other Anti-cancer therapies

Publication Date: 2026.02.12 QURIENT CO LTD

AI summary

The present disclosure relates to combinations of cyclin-dependent kinase 7 (CDK7) inhibitors and other therapeutic treatments, in particular other anti-cancer agents, and uses of such combination(s) in the treatment of cancers.